The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard® against the human papillomavirus (HPV), which causes cervical cancer. The research will evaluate the efficacy of Carraguard®, a clear gel made from the seaweed derivative carrageenan in preventing new HPV infections in women. According to the World Health Organization, approximately 440 million males and females are infected with HPV worldwide. The Centers for Disease Control estimates at least 20 million Americans have HPV... 
More...
More...